Combined Phase I/II Study of Epirubicin (Pharmorubicin), Carboplatin (Paraplatin) and Capecitabine (Xeloda) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates.

Trial Profile

Combined Phase I/II Study of Epirubicin (Pharmorubicin), Carboplatin (Paraplatin) and Capecitabine (Xeloda) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 18 Feb 2016

At a glance

  • Drugs Capecitabine (Primary) ; Carboplatin; Epirubicin
  • Indications Gastrointestinal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Sep 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 27 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top